Abstract: Among other things, the present disclosure provides compositions and methods for an elastomeric cross-linked polyester material. Such an elastomeric cross-linked polyester material, in some embodiments, comprises a plurality of polymeric units of the general formula (-A-B-)p, wherein p is an integer greater than 1; and a plurality of urethane cross-links each of which covalently links two polymeric units to one another, which two linked polymeric unit each had at least one free hydroxyl or amino group prior to formation of the crosslink.

Abstract: Among other things, the present disclosure provides compositions and methods for an elastomeric cross-linked polyester material. Such an elastomeric cross-linked polyester material, in some embodiments, comprises a plurality of polymeric units of the general formula (-A-B-)p, wherein p is an integer greater than 1; and a plurality of urethane cross-links each of which covalently links two polymeric units to one another, which two linked polymeric unit each had at least one free hydroxyl or amino group prior to formation of the crosslink.

Abstract: Among other things, the present disclosure provides compositions and methods for an elastomeric cross-linked polyester material. Such an elastomeric cross-linked polyester material, in some embodiments, comprises a plurality of polymeric units of the general formula (-A-B—)p, wherein p is an integer greater than 1; and a plurality of urethane cross-links each of which covalently links two polymeric units to one another, which two linked polymeric unit each had at least one free hydroxyl or amino group prior to formation of the crosslink.

Abstract: The subject invention provides a method for promoting wound healing in a patient in need thereof comprising contacting a wound of the patient with exosomes secreted by umbilical cord blood mononuclear cells (UCBMNCs) so as to thereby promote wound healing in the patient. The subject application also provides a method for promoting wound healing in a patient in need thereof comprising contacting a wound of the patient with a composition comprising one or more miRNA and a pharmaceutically acceptable carrier so as to thereby promote wound healing in the patient.

Abstract: The present disclosure relates to a differentiated cell population of endothelial cells derived from human pluripotent stem cells. The present invention also relates to a composition, a system and a kit comprising those cells and uses thereof. The present disclosure also described the combination of arterial ECs derived from human pluripotent stem cells with a microfluidic system to create a vascular kit for high-throughput drug screening and/or toxicology analysis. This technology may find particular use for the identification of drugs that may have a fetal cytotoxic effect.

Abstract: Among other things, the present disclosure provides compositions and methods for an elastomeric cross-linked polyester material. Such an elastomeric cross-linked polyester material, in some embodiments, comprises a plurality of polymeric units of the general formula (-A-B—)p, wherein p is an integer greater than 1; and a plurality of urethane cross-links each of which covalently links two polymeric units to one another, which two linked polymeric unit each had at least one free hydroxyl or amino group prior to formation of the crosslink.

Abstract: The invention relates to aspartic proteases, and particularly to aspartic proteases for plants. Disclosed are modified plant aspartic proteases, and methods for their manufacture, and uses thereof. Particularly contemplated are the uses of aspartic proteases in inducing skin desquamation.

Abstract: The present invention relates to methods of distinguishing between glutamine formed by cataplerosis or proteolysis. Sample from a subject may be assayed for deuteriated glutamine (following administration of deuteriated water (2H2O) and an agent that promotes excretion of glutamine from the subject). The methods are useful in clinical settings (e.g. to test whether or not patients are suffering from proteolysis or whether athletes are abusing anabolic drugs); and may be adapted for screening test compounds for cataplerotic or proteolytic activity.

Abstract: The present disclosure relates to a differentiated cell population of endothelial cells derived from human pluripotent stem cells. The present invention also relates to a composition, a system and a kit comprising those cells and uses thereof. The present disclosure also described the combination of arterial ECs derived from human pluripotent stem cells with a microfluidic system to create a vascular kit for high-throughput drug screening and/or toxicology analysis. This technology may find particular use for the identification of drugs that may have a fetal cytotoxic effect.

Abstract: The invention relates to an antimicrobial coating composition for coating articles comprising: an antimicrobial peptide and a nanoparticle bound to said antimicrobial peptide, wherein the composition is suitable to be bonded to the surface of the article. The composition can comprise a coating composition of medical devices and laboratory surfaces.

Abstract: The application concerns an isolated protein complex comprising polypeptide components: (i) UTP20 HUMAN or a fragment, variant or homologue thereof; (ii) PWP2 HUMAN or a fragment, variant or homologue thereof; (iii) WDR46_HUMAN or a fragment, variant or homologue thereof; (iv) UTP18 HUMAN or a fragment, variant or homologue thereof; (v) MPPIO HUMAN or a fragment, variant or homologue thereof; (vi) WDR3_HUMAN or a fragment, variant or homologue thereof; (vii) TBL3 HUMAN or a fragment, variant or homologue thereof; (viii) WDR36_HUMAN or a fragment, variant or homologue thereof; and (ix) N0C4L HUMAN or a fragment, variant or homologue thereof.

Abstract: The present invention relates to methods of distinguishing between glutamine formed by cataplerosis or proteolysis. Sample from a subject may be assayed for deuteriated glutamine (following administration of deuteriated water (2H2O) and an agent that promotes excretion of glutamine from the subject). The methods are useful in clinical settings (e.g. to test whether or not patients are suffering from proteolysis or whether athletes are abusing anabolic drugs); and may be adapted for screening test compounds for cataplerotic or proteolytic activity.